LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
- Elevations of GLP-1 and PYY - Reductions in Triglycerides and Uric Acid - 5th Clinical Study to Show Favorable Safety ProfileTHE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ — LexiconPharmaceuticals, Inc. (Nasdaq: LXRX), a…
September 13th, 2011
Posted in
Drug